|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> Starting from the BXPC3 cell line, we generated and profiled a TRAIL-resistant model of pancreatic cancer, testing the impact of the combined treatment <i>in vitro</i> with specific cytotoxicity and metabolic assays.
|
30809285 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TRAIL can stimulate the expression of uPA, IL-8, MMP-7 and MMP-9 in pancreatic cancer cell lines, especially in Colo357wt.
|
18397859 |
2008 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.
|
26138346 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
TRAIL-activating therapy has been promising, however, clinical trials have shown resistance and limited responses of pancreatic cancers.
|
26320171 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
|
11234897 |
2001 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined treatment with oncolytic adenovirus-mediated hSSTr2 and TRAIL gene provides the rationale for a clinical trial in pancreatic cancer.
|
19671855 |
2009 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
|
25482930 |
2014 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we observed increased sensitivity of G1-arrested pancreatic cancer cells towards TRAIL-induced apoptosis.
|
17304504 |
2007 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Geldanamycin, PS-341, and TRAIL triple combination may be a novel therapeutic strategy for pancreatic cancer.
|
15781649 |
2005 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we report that DHA enhances the efficacy of Apo2L/TRAIL for the treatment of pancreatic cancer.
|
22666346 |
2012 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
|
28476028 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, most pancreatic cancers are resistant to TRAIL therapy.
|
23833311 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we demonstrated that survivin downregulation with TRAIL expression greatly enhanced the cytotoxic death of pancreatic cancer cells after gemcitabine treatment.
|
26677013 |
2016 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer.
|
28572836 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment.
|
30075209 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MUC5AC inhibits TRAIL‑induced apoptosis in human pancreatic cancer and may serve as an important indicator in diagnosis and prognosis.
|
23292004 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that TRAIL gene therapy in combination with gemcitabine might be a useful therapeutic approach for treating metastatic pancreatic cancers.
|
15486557 |
2005 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our studies support an innovative application of available PARP inhibitors or new cytoplasmic PARP-1 antagonists to enhance TRAIL therapy for TRAIL-resistant pancreatic cancers.
|
30614530 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
|
24204567 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.
|
25684663 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
|
28188806 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeted inhibition of OPG binding to TRAIL may represent a therapeutic approach in the treatment of pancreatic cancer.
|
23219833 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TRAIL mice displayed significantly decreased tumor volumes and an enhanced overall survival in pancreatic cancer.
|
26390425 |
2016 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study explored the possibility of sensitizing pancreatic cancer to gemcitabine chemotherapy by combining the chemotherapy with the proapoptotic genes Bax and TNF-related apoptosis-inducing ligand (TRAIL).
|
17984977 |
2008 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings give new insight into the resistance mechanisms of pancreatic cancer towards TRAIL-mediated apoptosis.
|
11848467 |
2002 |